In conclusion, this study firstly provides the experience of an in-house molecular diagnostics system in cancer pharmacogenomics, especially EGFR mutations in lung cancer, from setup to routine practice and quality control in Taiwan. The gene discussed is EGFR; the disease is lung carcinoma.